Table 1.
Baseline Characteristics of Women in the Hormone Trials
| CEE+MPA Trial | CEE Trial | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | CHD | Control | CHD | ||||||
| N | % | N | % | N | % | N | % | P-value1 | |
| Ethnicity | 0.87 | ||||||||
| 25 | 11 | ||||||||
| White | 424 | 88.0 | 183 | 89.3 | 3 | 75.5 | 7 | 76.0 | |
| Black | 28 | 5.8 | 12 | 5.9 | 58 | 17.3 | 26 | 16.9 | |
| Other | 30 | 6.2 | 10 | 4.9 | 24 | 7.2 | 11 | 7.1 | |
| Smoking status | <0.001 | ||||||||
| 16 | |||||||||
| Never | 268 | 56.4 | 90 | 45.5 | 9 | 51.8 | 72 | 47.7 | |
| 12 | |||||||||
| Past | 171 | 36.0 | 66 | 33.3 | 8 | 39.3 | 48 | 31.8 | |
| Current | 36 | 7.6 | 42 | 21.2 | 29 | 8.9 | 31 | 20.5 | |
| Alcohol use | 0.006 | ||||||||
| 17 | 10 | ||||||||
| Non drinker | 221 | 46.3 | 107 | 52.5 | 4 | 52.1 | 2 | 67.5 | |
| 13 | |||||||||
| ≤1 drink/day | 193 | 40.5 | 78 | 38.2 | 3 | 39.8 | 42 | 27.8 | |
| >1 drink/day | 63 | 13.2 | 19 | 9.3 | 27 | 8.1 | 7 | 4.6 | |
| Physical activity, METs | 0.01 | ||||||||
| Inactive | 61 | 14.7 | 40 | 23.1 | 68 | 22.9 | 33 | 24.3 | |
| <5 | 89 | 21.4 | 43 | 24.9 | 73 | 24.6 | 44 | 32.4 | |
| 5–12 | 104 | 25.0 | 43 | 24.9 | 65 | 21.9 | 26 | 19.1 | |
| ≥12 | 162 | 38.9 | 47 | 27.2 | 91 | 30.6 | 33 | 24.3 | |
| Treated diabetes | 22 | 4.6 | 28 | 13.7 | 20 | 6.0 | 36 | 23.4 | <0.001 |
| History of hypertension | <0.001 | ||||||||
| 17 | |||||||||
| Never | 274 | 65.9 | 86 | 50.0 | 2 | 58.7 | 55 | 41.0 | |
| Untreated | 37 | 8.9 | 20 | 11.6 | 18 | 6.1 | 15 | 11.2 | |
| 10 | |||||||||
| Treated | 105 | 25.2 | 66 | 38.4 | 3 | 35.2 | 64 | 47.8 | |
| History of high cholesterol | 66 | 16.0 | 43 | 25.3 | 54 | 18.6 | 36 | 27.3 | <0.001 |
| LVH on electrocardiogram | 23 | 4.8 | 11 | 5.4 | 23 | 6.9 | 22 | 14.6 | 0.02 |
| History of CVD | 53 | 11.1 | 48 | 24.2 | 59 | 17.9 | 42 | 28.0 | <0.001 |
| Baseline aspirin use | 105 | 21.8 | 56 | 27.3 | 75 | 22.4 | 50 | 32.5 | 0.007 |
| Baseline statin use | 35 | 7.3 | 34 | 16.6 | 35 | 10.4 | 21 | 13.6 | <0.001 |
| N | Mean (Std) | N | Mean (Std) | N | Mean (Std) | N | Mean (Std) | ||
| 33 | 15 | ||||||||
| Age at screening, years | 482 | 66.7 (6.9) | 205 | 66.1 (7.54) | 5 | 66.4 (6.6) | 4 | 67.4 (6.2) | 0.84 |
| Body-mass index, kg/m2 | 478 | 27.8 (5.5) | 205 | 29.0 (5.7) | 334 | 29.4 (5.6) | 154 | 30.2 (5.7) | 0.004 |
| Height, cm | 480 | 161.0 (6.7) | 205 | 161.2 (6.5) | 334 | 161.4 (6.4) | 154 | 160.8 (6.2) | 0.80 |
| Weight, kg | 480 | 72.2 (15.3) | 205 | 75.5 (16.0) | 335 | 76.6 (15.3) | 154 | 78.2 (16.1) | 0.008 |
| Waist to hip ratio | 479 | 0.8 (0.1) | 205 | 0.8 (0.1) | 335 | 0.8 (0.1) | 154 | 0.9 (0.1) | <0.001 |
| Waist, cm | 480 | 86.8 (13.7) | 205 | 90.9 (13.8) | 335 | 90.9 (13.2) | 154 | 95.1 (13.9) | <0.001 |
| Systolic BP | 482 | 129.7 (17.8) | 205 | 134.2 (18.5) | 335 | 130.2 (16.7) | 154 | 139.6 (19.0) | <0.001 |
| Diastolic BP | 482 | 74.9 (9.3) | 205 | 76.9 (10.3) | 334 | 75.9 (9.00 | 154 | 76.3 (10.8) | 0.02 |
1
P-value quantifies marginal association of baseline characteristic with incident CHD. Obtained from a logistic regression model, adjusted for treatment assignment (CEE, CEE placebo, E+P, E+P placebo) using a 1 degree of freedom test for association; except for the categorical variables ethnicity, smoking, alcohol use, physical activity, and use of hypertension medication.